Impact of sensor-augmented pump therapy with predictive low-glucose management on hypoglycemia and glycemic control in patients with type 1 diabetes mellitus: 1-year follow-up
| Autor: | Maira García-Jaramillo, Martín Rondón, Lucia B. Taboada, Fabian Mauricio León Vargas, Diana Henao, Oscar Muñoz, Ana María Gómez, Guillermo Leguizamón |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Time Factors Adolescent Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Hypoglycemia 03 medical and health sciences Young Adult 0302 clinical medicine Insulin Infusion Systems Diabetes mellitus Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Insulin In patient 030212 general & internal medicine Glycemic Retrospective Studies Glycated Hemoglobin Type 1 diabetes integumentary system business.industry Area under the curve Retrospective cohort study General Medicine medicine.disease Prognosis Diabetes Mellitus Type 1 Hyperglycemia Female business Biomarkers Follow-Up Studies |
| Zdroj: | Diabetesmetabolic syndrome. 13(4) |
| ISSN: | 1878-0334 |
| Popis: | Aims To describe real-life experience with sensor-augmented pump therapy with predictive low-glucose management (SAPT-PLGM), in terms of hypoglycemia and glycemic control after one year of follow-up in T1D patients with hypoglycemia as the main indication of therapy. Methods Retrospective cohort study under real life conditions. Baseline and one-year follow-up variables of glycemic control, hypoglycemia and glycemic variability were compared. Results Fifty patients were included, 31 on prior treatment with SAPT with low-glucose suspend (LGS) feature and 19 on multiple dose insulin injections (MDI). Mean HbA1c decreased in the MDI group (8.24%–7.08%; p = 0.0001). HbA1c change was not significant in the SAPT-LGS group. Area under the curve (AUC) below 70 mg/dl improved in both SAPT-LGS and MDI groups while AUC, %time and events below 54 mg/dl decreased in SAPT-LGS group. Glycemic variability improved in the MDI group. Less patients presented severe hypoglycemia with SAPT-PLGM in both groups, however the change was non-significant. Conclusions Under real life conditions, SAPT-PLGM reduced metrics of hypoglycemia in patients previously treaded with MDI and SAPT-LGS without deteriorating glycemic control in SAPT-LGS patients, while improving it in patients treated with MDI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect